Herning Hospital, Surgical research dep.
Herning, Central Jutland, 7400, Denmark
NCT Number: NCT00388128
The purpose of this study is to evaluate the change in Walking capacity after an intake of caffeine. The study design is cross-over and follow-up of 80 patients with leg pain caused by narrowing of their leg arteries, Peripheral Vascular Disease (PAD), stage II. Half of all will be revascularised, follow up will be after 3 months. It is hypothesized that caffeine (6mg/kg) can be a cheap, safe drug before walking exercise. Primary endpoint is maximum walking distance (MWD), treadmill-testing,(constant load, 0%,2m/h). Secondary endpoints are pain free walking distance (PWD), maximum muscle strength, endurance, reaction speed, balance, cognitive function, health related quality of life (SF-36).
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 3
Herning, Central Jutland, 7400, Denmark
PAD has a prevalence of 15-20 % in an elderly (>50) western population. PAD can not be seen in isolation but represents the peripheral manifestation of a generalized artherosclerosis. The co-morbidity with coronary or cerebralartherosclerosis depends on the degree of severity of PAD, the relative risk of a death (predominantly cardiac) is increased by a factor 4. From af medical and a socio-economic point of view there is the need to control the PAD complication rate and related treatment costs as effectively as possible.
The aim of any treatment of intermittent claudication is a clinically relevant improvement in the patient´s mobility and quality of life.
There is agreement, that physical training does improve the collateralisation of vascular lesions, the rheologic properties of blood and lead to a shift from glycolytic to oxidative muscle fibers in the working musculature which increases the capillary density. The effect of physical training is also to modify the patients risk factor profile, even moderate training increase the insulin receptor sensitivity and the fibrinolytic activity and decrease the dLDL/HDL ratio and the diastolic blood pressure in hypertensive patients - and thereby decrease the overall cardiac mortality.
This is a Phase 3, 12-week, double-blind, randomized, placebo-controlled cross-over and a follow-up study with 80 patients with intermittent claudication, half of which will be revascularized.
The objectives of this study are to evaluate the efficacy of caffeine (6mg/kg)and the revascularisation procedure. The primary end-point will be maximal walking distance (MWD) in both groups of patients. Other efficacy measures will include claudication onset time (PWD), changes in Ankle Brachial Index (ABI), Quality of Life (QoL), cognitive function, plasma response of Vascular Endothelian Growth Factor (VEGF, FGF). Safety variables will include routine hematology parameters and adverse events.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
Time frame: during test 1 and 3
Time frame: during treadmill test
Time frame: treadmill test
Time frame: At end of each test
Time frame: At end of each test
Time frame: in all tests
Time frame: in all tests
Time frame: in all tests
Time frame: in first and third test
Time frame: before and after 1. and 2. test
University of Aarhus
Other
Effects of Caffeine in Patients With Intermittent Claudication.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05232474
Arterial Occlusive Diseases, Arteriosclerosis
Nijmegen, Netherlands
View Trial DetailsNCT03204825
Agnosia, Arterial Occlusive Diseases
Glasgow, Strathcylde, United Kingdom
View Trial DetailsNCT03784729
Bone Diseases, Cardiovascular Diseases
Beijing, China
View Trial DetailsNCT05335161
Arterial Occlusive Diseases, Arteriosclerosis
West Lafayette, Indiana, United States
View Trial Details